
    
      This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to be
      conducted in 2 stages (Stage A and Stage B). Stage A is an ascending single-dose
      placebo-controlled study planned to consist of 2 cohorts. Stage B is a parallel-treatment
      group study planned to consist of a placebo group and 2 active treatment groups of temanogrel
      doses selected based on safety and tolerability data in Stage A.
    
  